BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 532 filers reported holding BIO-TECHNE CORP in Q3 2022. The put-call ratio across all filers is 0.22 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,511,887 | -38.9% | 21,101 | -40.0% | 0.02% | -42.3% |
Q1 2024 | $2,476,039 | -7.0% | 35,176 | +1.9% | 0.03% | -18.8% |
Q4 2023 | $2,663,255 | +4.3% | 34,516 | -8.0% | 0.03% | -8.6% |
Q3 2023 | $2,554,259 | -14.0% | 37,524 | +3.2% | 0.04% | -12.5% |
Q2 2023 | $2,968,393 | +7.5% | 36,364 | -2.3% | 0.04% | 0.0% |
Q1 2023 | $2,760,016 | -7.1% | 37,202 | +3.8% | 0.04% | -16.7% |
Q4 2022 | $2,971,165 | +31.5% | 35,849 | +350.5% | 0.05% | +11.6% |
Q3 2022 | $2,260,000 | -12.3% | 7,958 | +7.0% | 0.04% | -17.3% |
Q2 2022 | $2,577,000 | -10.6% | 7,435 | +11.7% | 0.05% | +8.3% |
Q1 2022 | $2,882,000 | -15.2% | 6,655 | +1.2% | 0.05% | -9.4% |
Q4 2021 | $3,400,000 | +18.6% | 6,573 | +11.1% | 0.05% | -1.9% |
Q3 2021 | $2,867,000 | -25.2% | 5,916 | -30.5% | 0.05% | -22.9% |
Q2 2021 | $3,833,000 | +28.6% | 8,512 | +9.1% | 0.07% | +11.1% |
Q1 2021 | $2,980,000 | +21.8% | 7,802 | +1.3% | 0.06% | +18.9% |
Q4 2020 | $2,446,000 | +27.3% | 7,703 | -0.7% | 0.05% | +12.8% |
Q3 2020 | $1,922,000 | +1.6% | 7,757 | +8.3% | 0.05% | -4.1% |
Q2 2020 | $1,892,000 | – | 7,164 | – | 0.05% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 46,500 | $16,119,000 | 8.75% |
Montanaro Asset Management Ltd | 93,950 | $32,567,000 | 4.90% |
Jackson Square Partners, LLC | 556,157 | $192,786,000 | 4.50% |
STONE RUN CAPITAL, LLC | 22,405 | $7,767,000 | 3.91% |
Ownership Capital B.V. | 655,654 | $227,276,000 | 3.90% |
Brown Capital Management | 839,587 | $291,034,000 | 3.90% |
Sandhill Capital Partners LLC | 97,382 | $33,757,000 | 3.61% |
DF DENT & CO INC | 684,026 | $237,111,000 | 3.34% |
Westwind Capital | 27,946 | $9,687,000 | 3.17% |
MAIRS & POWER INC | 655,930 | $227,371,000 | 2.72% |